Arthritis drug shows promise for rare, Life-Threatening skin conditions
NCT ID NCT06474078
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tested the drug tofacitinib (XELJANZ) in 20 adults with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), rare and severe skin reactions often caused by medications. The main goal was to see how quickly the skin healed completely. Researchers also tracked deaths, hospital stay length, side effects, and eye complications. The study was small and had no placebo group, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib (XELJANZ)
- What this could lead to
- If it works, this could point toward a faster skin-healing treatment for severe drug reactions like SJS/TEN.
- What could go wrong
- This was a very small pilot study with only 20 people and no comparison group, so results may not apply broadly. Tofacitinib can increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEVENS-JOHNSON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye surgery breakthrough? tiny trial tests humira injection during corneal implant
- Could a simple ingredient boost dry eye drops?
- Planned study on severe skin reactions withdrawn before starting
- Can a white blood cell booster heal a rare skin emergency?
- Contact lens coating replenisher tested for rare eye conditions
- Small study tests drug for rare, Life-Threatening skin condition